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Although observational studies (OSs) of 
human subjects are considered to be more 
practical and closer to real-life daily prac-
tices than are clinical trials (CTs), the trans-
parency that the scientific community de-
mands for the latter is considered irrelevant 
for OSs. Recommendations that OSs should 
be publicly registered, as occurs for CTs, has 
been debated for years, with supporting, 
dissenting, and neutral views (1–8). Some 
investigators conducting epidemiological 
OS already register their studies: As of 29 
January 2014, 29,826 OSs are registered in 
ClinicalTrials.gov (18.6% among more than 
160,000). However, the great majority of 
OSs are unregistered, despite the fact that 
OSs represent a large fraction of published 
health-related research.
SURVEYING THE LANDSCAPE
In order to understand the types of studies 
that are currently published and registered 
in the biomedical literature, we searched 
PubMed for papers that (i) had abstracts; 
(ii) pertained to humans; (iii) were not clas-
sified as reviews or systematic reviews, me-
ta-analyses, case reports, guidelines, editori-
als, or consensus statements; and (iv) were 
published in 2011. Of 400,601 such papers, 
23,350 (6%) were classified by PubMed as 
“randomized controlled trials” (RCTs), and 
377,251 did not have this tag. Using a ran-
dom sample of 50 of the 377,251 papers, 
we determined that 36 (72%) were nonran-
domized studies; only two listed a registra-
tion number, of which one was a single-arm 
clinical trial and the other a large case-con-
trol study. Using a random sample of 0.5% 
(n = 118) of the 23,350 
papers, we found that 
89 (75%) were indeed 
RCTs and 11 (9%) had 
OS design but used data 
from RCTs; 22 PubMed 
records had a listed reg-
istration number. These 
observations suggest 
that publications of re-
sults from OSs far out-
number publications 
from RCTs, with almost 
300,000 versus 20,000 
publications of the two 
study design types per 
year, respectively. Reg-
istration numbers still 
accompany only ~20% of RCTs, and regis-
tration of OSs is distinctly uncommon; one 
exception may be OSs that use data from 
RCTs. We found five such cases in our sam-
pling, but the registration record always re-
ferred to the original RCT and provided no 
meaningful information on the study design 
of the specific OS.
In observational research, it is some-
times difficult to define what constitutes a 
single study: an analysis, a set of analyses, 
or a protocol. However, the majority of OS 
results appearing in peer-reviewed journals 
are unanticipated; that is, only a small set of 
authors, funders, and reviewers know about 
the study’s existence before publication.
PROS AND CONS
There are several postulated benefits in sys-
tematically registering all OSs: increasing 
transparency and credibility, improving the 
peer-review process and ethical conduct 
of studies, and ensuring that the totality of 
evidence is publicly available (1). Moreover, 
registration of OSs may enhance commu-
nication regarding explored, but not pub-
lished, hypotheses (3), facilitate systematic 
reviews and research collaborations (8), and 
reduce redundancy and funding committed 
to research questions for which adequate 
studies have already been conducted or are 
being performed (9), allowing published 
evidence to be better placed in context.
Registration of CTs started as a means 
of deterring (and detecting) selective re-
porting (10). OSs with negative results 
are believed to be less frequently reported 
than those with positive findings (6). In-
deed, nearly all published OS results re-
port some significant findings, and many 
report implausibly large effects (11). This 
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People watching. In OSs, researchers make and record observations 
according to a study protocol that does not include an intervention.
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high rate of likely false-positive findings 
has led policy-makers and the public to 
regard OS results with skepticism (12). 
Young and Karr (13) found that none of 
52 major claims from selected health- 
related OSs were validated in RCTs. Swaen 
et al. (14) showed that OSs without pre-
specified hypotheses are more likely to 
yield published false-positive results than 
are OSs based on predefined hypotheses. 
Simply being “hypothesized” does not, of 
course, itself infer greater validity to a study 
observation, but hypothesis-based research 
is more likely than post hoc analysis to in-
volve study populations appropriate for 
testing the hypothesis, to measure relevant 
exposures and outcomes in necessary de-
tail, and to collect pertinent covariate in-
formation (7). Moreover, hypothesis-based 
research is more likely to be appropriately 
powered and thus less likely to produce 
inflated associations (15). Therefore, some 
(7, 14), but not all (3, 16), authors speculate 
that conducting OSs with publicly declared 
prespecified hypotheses might reduce the 
rate of false-positive findings. Prospective 
registration of OSs also may encourage in-
vestigators to publish study results irrespec-
tive of whether they meet some nominal 
level of statistical significance because pub-
lication is a basic requirement of research 
ethics (17) and scholarship.
A potential disadvantage of registering 
highly exploratory, hypothesis-generating 
research with complex, meandering analyses 
is the burden of ongoing serial amendments 
(1, 6, 8) and the resulting hindrance of new 
idea generation (4, 8), as well as reduction in 
the analyses of end points not prespecified 
because they were conceived after the study 
started (18). However, there is no compel-
ling reason why new concepts should be hin-
dered; they just need to be identified as post 
hoc observations. Such disclosure allows 
others to fully understand and openly debate 
the nature and merit of the analyses. There is 
no evidence that registering CTs has led to 
fewer hypotheses being tested or a decline in 
secondary analysis of trial data. Conversely, 
there is greater recognition that hypotheses 
and analyses for testing them need to be 
specified a priori (19, 20); without such de-
lineation, study results can lead to biased re-
framing of the hypothesis or cherry-picking 
among unspecified end points.
Another concern is that competitors may 
“steal” novel ideas from a registry, complete 
the analyses, and publish the results first. 
However, wide adoption of OS registration 
and transparent sharing of OS data will docu-
ment primacy of investigators who first reg-
istered the idea for a given data set. The act of 
registering a protocol and study hypotheses 
can serve as a claim to the conceptual under-
pinnings of a study.
THE REGISTRATION CHALLENGE
In contrast to CTs, which require prospec-
tive data collection and follow-up of par-
ticipants, analyses of some OSs can be per-
formed readily in minimal time whenever 
required data have been collected, perhaps 
as part of a prior survey or a byproduct of 
health care activities (for example, admin-
istrative or billing databases, disease regis-
tries). In these cases, registering a protocol 
or a full analysis plan may not qualify as 
prospective. Theoretically, an investigator 
can mine the available data, notice some 
provocative results, and build a protocol 
and analysis plan around the selected results 
while spuriously claiming that the plan was 
prospectively conceived. Therefore, for ex-
isting OS data sets it is essential to publicly 
disclose what variables have been collected 
and are available for analysis. Such disclo-
sure would define, at least in part, the ana-
lytical space in which analyses can be read-
ily performed.
Epidemiologists, their professional orga-
nizations, and journal editors should endorse 
OS registration (1) because the reasons sup-
porting registration of CTs outlined in the 
Ottawa statement (21) also are applicable to 
OSs (Table 1). However, epidemiology pro-
fessional organizations have not yet done so, 
likely because of perceived idiosyncratic fea-
tures and objectives of observational versus 
experimental research (22). OSs use a much 
wider range of designs, methods, and data 
sources than do CTs (3), arguably making it 
difficult to comprehensively and meaningful-
ly summarize all possible scenarios tailored 
to a fixed number of informational elements 
recorded in a registry. Nonetheless, this bot-
tleneck does not apply to all OSs because a 
fair number are indeed registered in resourc-
es such as ClinicalTrials.gov, and researchers 
can tailor their information to fit a typical CT 
registry format.
Last, a critical challenge is the complete-
ness and quality of the information posted on 
the registry. A recent study of registered OSs 
showed large differences in the quantity and 
quality of information provided among and 
within registries (23). Still, the willingness of 
investigators to register their studies should 
be applauded because readers are informed 
about the existence of an OS and can contact 
the investigators for further information.
OS PROTOCOLS AND INVESTIGATORS
Epidemiological research on human sub-
jects must comply with accepted ethical 
standards that demand approval of the study 
protocol by institutional review boards 
(IRBs) (17, 24), particularly when investi-
gators plan to obtain personal information 
directly from participants or will otherwise 
use potentially identifiable personal infor-
mation about them. If investigators have 
submitted an OS protocol that is approved 
by an IRB, there is little additional burden to 
register that protocol on a publicly available 
registry. Amendments may be registered as 
new knowledge becomes available, creating 
a publicly available audit trail.
If IRBs approve studies lacking fully de-
fined prespecified hypotheses, there is little 
reason for not making protocols available 
through subsequent registration. Although 
controversial, registration is common in 
large patient cohorts and biobanks estab-
lished to collect information for future use 
(25). These studies are likely to have explicit 
protocols for recruiting participants, col-
Table 1. Rationale for registration of CTs. 
The Ottawa statement is provided in (21). All 
rationales listed are applicable to OSs.
Ethical
•  Respect the investigator-participant covenant 
to contribute to biomedical knowledge by 
making trial methods and results public
• Provide global open access to information
•  Reduce unnecessary duplication of invested 
research resources through awareness of 
existing trials
•  Assure accountability with regard to global 
standards for ethical research
•  Enable monitoring of adherence to ethical 
principles and process 
Scientific
•  Increase the reliability and availability of evi-
dence on which health care decisions are based
• Improve trial participation
• Increase opportunities for collaboration
•  Ensure transparency of trial design and 
methods
•  Provide open review of protocols to improve 
trial quality and refine methods
•  Provide means for identification and preven-
tion of biased underreporting or over- 
reporting of research
• Accelerate knowledge creation
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lecting samples, and what measurements 
are to be made. The list of measurements 
may be updated and expanded over time, 
even when future analyses are unanticipat-
ed. As a future goal, all analyses performed 
on the data can be recorded in a computer 
log. This would show the path followed in 
exploratory analyses and facilitate replica-
tion by providing the exact analytical codes 
applied in additional data and studies. Some 
scientific fields are experimenting with live 
streaming, in which analyses are shared in 
real time. This technology allows the scien-
tific community to observe, as it happens, 
the evolution of a research project and its 
analyses (26).
STAKEHOLDER SUPPORT
Influential stakeholders may provide incen-
tives to encourage OS registration. Although 
a few high-profile journals encourage regis-
tration (2), the International Committee of 
Medical Journal Editors (ICMJE) has explic-
itly stated that OSs do not require registration 
(27). Unless ICMJE changes its position or 
leading medical journals independently start 
to require prospective registration of OSs, rec-
ommendations for registration by individuals 
will have limited influence because the major 
incentive of “license to publish” is missing.
The World Medical Association (WMA) 
lagged behind the ICJME, the World Health 
Organization (WHO), and various regulatory 
agencies (28, 29) in supporting the mandato-
ry prospective registration of CTs, introduc-
ing this requirement in the 2008 version of the 
Declaration of Helsinki (17). In the 2013 revi-
sion (30), the WMA took the lead in requir-
ing the registration of “every research study 
involving human subjects,” thus requesting 
OS registration up front. Such a decision 
could have an important impact because the 
behavior of physicians in complying with the 
ethical principles of such a declaration will 
influence the mindset of other professionals 
involved in observational research.
The critical role that WHO played in the 
registration of CTs is well known (31), in-
cluding establishment of the international 
standards for CT registries (32) and the In-
ternational CT Registry Platform (ICTRP) 
(33). If the ICTRP’s explicit mission truly is 
to “ensure that a complete view of research 
is accessible to all those involved in health-
care decision making” (32), and if six of the 
eight scientific, ethical, and moral reasons 
why WHO supports registration of CTs (33) 
are equally applicable to observational re-
search (Table 2), then WHO should support 
mandatory registration for OSs. Implemen-
tation of the ICJME request, in 2005, to reg-
ister CTs (34) revealed the need to involve 
key agents of the research process to boost 
study registration. As the only stakeholder 
that approves all human research, IRBs 
could require that all OSs be registered as a 
condition of ethics approval.
We propose that public agencies and 
charitable organizations that fund medical 
research require prospective registration of 
OSs as a condition for funding, analogous 
to requiring IRB approval before study ini-
tiation. Major funding agencies such as the 
U.S. National Institutes of Health, which 
demand protocols before funding research, 
could garner broad acceptance for requiring 
public registration of OSs before launching 
a study. The same requirement could apply 
for competing grant renewals with exten-
sions to collect new data and perform new 
analyses. The decision by the UK National 
Institute for Health Research Health Tech-
nology Assessment Programme to with-
hold a proportion of a research grant until a 
study report has been submitted for publica-
tion (35) underscores the power wielded by 
funders. In a similar manner, funders may 
consider withholding funding until the OS 
protocol is registered in sufficient detail.
Table 2. Scientific, ethical, and moral reasons to support prospective registration of CTs 
[WHO, (33)].
1.  There is a need to ensure that decisions about health care are informed by all of the available 
evidence.* 
2.  It is difficult to make informed decisions if publication bias and selective reporting are present.* 
3.  The Declaration of Helsinki states that “every trial must be registered in a publicly accessible data-
base before recruitment of the first subject.” † 
4.  Improving awareness of similar or identical trials will make it possible for researchers and funding 
agencies to avoid unnecessary duplication.* 
5.  Describing clinical trials in progress can make it easier to identify gaps in clinical trials research.* 
6.  Making researchers and potential participants aware of recruiting trials may facilitate recruitment.* 
7.  Enabling researchers and health-care practitioners to identify trials in which they may have an 
interest could result in more effective collaboration among researchers. The type of collaboration 
may include prospective meta-analysis.* 
8.  Registries checking data as part of the registration process may lead to improvements in the 
quality of clinical trials by making it possible to identify potential problems (such as problematic 
randomization methods) early in the research process.
Table 3. Sharing OSs with the scientific community. Access could be extended to a lay audi-
ence; however, the nature of the information will be most useful to scientists. Modified from 
Khoury et al. (26).
Information type Comments 
Data set registration Should be feasible to achieve in large scale; each data set registers the 
variables that it has collected and their definitions; this would allow knowing 
how many studies with how many participants who have measured variables 
or markers of interest, instead of guessing what data are available on that 
marker beyond what has been published 
Availability of de-
tailed data 
Individual-level (raw) data are made available; this practice may be subject to 
policy/consent/privacy constraints for past studies and their data; easier to 
anticipate and encourage in the design of future studies 
Availability of data, 
protocols, and analy-
ses codes 
Optimal ability to evaluate the reproducibility of analyses, to maximize the 
integration of information across diverse studies, and to allow improvements 
on future studies based on exact knowledge of what was done in previous 
studies 
Live streaming of 
analyses 
Investigators not only post all their data and protocols online, but analyses 
are done and shown in real time to the wider community as they happen. 
Live streaming can be coupled with crowd sourcing of analyses across large 
communities of analysts
*Reasons applicable to OSs. †This wording has been broadened in the 2013 revision of the Declaration of Helsinki (30): 
“Every research study involving human subjects must be registered in a publicly accessible database before recruitment 
of the first subject.”
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DATA SHARING
Beyond protocol registration for OSs, spon-
sors and investigators should consider shar-
ing more OS information with the scientific 
community through a central repository 
in order to avoid fragmenting information 
among multiple registries (Table 3). Mini-
mum information should include the study 
design, mode of data collection and out-
comes, number of participants, and a full 
list of available measurements.
At the other end of the information- 
sharing spectrum, one could publicly dis-
close raw anonymized data at the individual-
participant level and update the information 
as new data become available, provided in-
formed consent stipulations have been pre-
arranged and met. Ideally, raw data would 
be registered along with analysis codes. For 
some types of research, such as microarray 
analyses, most high-profile journals already 
require raw data, protocols, and analytical 
algorithms to be deposited in public plat-
forms as a prerequisite to publication. This 
practice of data disclosure is becoming 
widespread (36). These examples suggest 
that the principle of having journals spear-
head registration and public transparency is 
also feasible for OSs, as it has been for CTs 
(10). Eventually, both journals and funders 
may need to apply pressure to achieve desir-
able levels of transparency.
If, as Hernán and Wilcox (37) have stated, 
all study data “unless destroyed or lost, will 
one day be in the public domain,” why should 
the key information describing an OS pro-
tocol not be publicly disclosed by means of 
prospective registration? Funders are pivotal 
in the registration process, just as they were 
in demanding open access to study results 
(38). ICMJE should consider revisiting its 
current position on this topic and encourage 
up-front registration of OSs. We suggest that 
an independent body such as WHO take the 
lead in establishing international standards 
for OS registration. In the long run, the ad-
vantages for society and the enhanced cred-
ibility of epidemiological research should 
outweigh any alleged disadvantages.
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